Journal
CLINICAL OPHTHALMOLOGY
Volume 13, Issue -, Pages 1115-1122Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OPTH.S184412
Keywords
keratoconjunctivitis sicca; dry eye disease; cyclosporine A
Categories
Funding
- US Public Health Service from National Eye Institute, National Institutes of Health, Bethesda, MD [RO1EY10056, P30-EY025585]
- Research to Prevent Blindness, New York, NY
Ask authors/readers for more resources
Dry eye disease (DED) is a multifactorial disease of ocular surface and tear film, and is a common disorder treated by eye care providers. It is well established that ocular surface inflammation has an important role in the pathophysiology of DED and that anti-inflammatory cyclosporine A (CsA) improves the treatment outcomes of most patients with DED. The purpose of this review is to provide guidance for practitioners in the use of topical CsA for the management of DED to improve patient satisfaction and the quality of life.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available